Dichrostachys glomerata

Other Names

Acacia Saint DomingueAderAfrican pepperAfrican sickle bushAromaArzikAshy baboolBell mimosaBurliCailliea dichrostachysCailliea glomerataCailliea nutansChinese lantern treeDesmanthus callistachysDesmanthus leptostachysDesmanthus nutansDesmanthus trichostachysDichrostachys arboreaDichrostachys caffraDichrostachys cinereaDichrostachys cinerea subsp. africanaDichrostachys forbesiiDichrostachys glomerata var. grandifoliaDichrostachys lugardiaeDichrostachys nutansDichrostachys nutans var. grandifoliaDichrostachys nyassanaDichrostachys platycarpaEdatariErgett-dimmoHegamHeghemHurgamHurganKadadKadadaKaddadKalahari Christmas treeKalemanjovuKansalonsaloKatengeKékéMarabou thornMarabúMimosa cinereaMimosa clochetteMimosa divergensMimosa glomerataMimosa nutansMimosa sanguineaMimosa variaMpangaraNdole pepperOmubambanjobePiptadenia stenadeniaPrincess EarringsSekelbosSekelsbosShamiSickle bushSicklebushSintéUm KedadVadavinaWest African sickle bush

Synopsis

Dichrostachys glomerata: A Comprehensive Reference Article

1. Identity, Taxonomy, and Natural Source

1.1 Botanical and Taxonomic Classification

Dichrostachys glomerata (Forssk.) Chiov. is also known by the species name Dichrostachys cinerea (L.) Wight & Arn., with Cailliea dichrostachys being another listed synonym; it belongs to the family Mimosaceae (also classed under Leguminosae or Fabaceae). The basionym Mimosa glomerata was published by Forsskål in 1775, and the combination Dichrostachys glomerata was formally established by Chiovenda in 1915. In current botanical databases, Dichrostachys glomerata (Forssk.) Chiov. is treated as a synonym of Dichrostachys cinerea subsp. africana Brenan & Brummitt (Fabaceae). In commercial and research literature, however, the name Dichrostachys glomerata continues to be used on supplement labels and in peer-reviewed publications.

1.2 Morphology and Natural Habitat

Dichrostachys glomerata is a semi-deciduous to deciduous tree up to 7 meters tall with an open crown. Bark on young branches appears green and hairy, but dark grey-brown and longitudinally fissured on older branches and stems. The plant is a shrub or small tree armed with spines terminating short lateral twigs, with leaves bearing 2–19 pairs of pinnae and leaflets ranging from 1–11 mm in length.

Also referred to as D. cinerea and belonging to the Leguminosae family (Mimosaceae), it is a deciduous small tree or shrub found from Senegal to Western Cameroon, and extending across Africa to Sudan, Uganda, and Zaire. It is widespread in Africa and India, and is considered an invasive species in the Caribbean. In savannah, it is often very common and forms thickets on disturbed scrub lands.

1.3 Common Names and Vernacular Designations

The plant produces edible fruits that are mostly elongated pods, fleshy, woolly, leathery, or papery, containing several seeds that split open in the majority of cases. The pod is known as "dundu" in Hausa, "burli" in Fulani, "Kara" in Yoruba, and "ami ogwu" in Igbo. It has also been referred to in English as "sickle bush" in some sources. In the Cameroonian food tradition it is sometimes called "ndole pepper" or "African pepper" informally.

1.4 Common Forms and Preparations as a Supplement

The primary plant part used commercially is the dried fruit pod. Dyglomera® is described as an aqueous ethanol extract of the fruit pods of Dichrostachys glomerata, a Cameroonian spice. Dyglomera® is an aqueous extract of DG standardized to a minimum of 10% polyphenols. A more recently characterized extract is standardized more stringently: one standardized Dichrostachys glomerata extract (DGE) used in clinical research was standardized to contain ≥25% total polyphenols, expressed as gallic acid equivalents (GAE). Commercial trade names appearing in peer-reviewed and trade literature include Dyglomera®, DygloFit®, DYG-400®, and Somnoril™, all derived from the same source plant. A recommended adult daily serving cited by Gateway Health Alliances for its Dyglomera/DygloFit product is 400 mg. For the Somnoril formulation, the recommended adult daily serving is listed as 300 mg.

2. Traditional and Historical Use

2.1 Culinary Use in West and Central Africa

The dry dehiscent constricted fruit pods of Dichrostachys glomerata are commonly used as spices in a traditional soup of the western provinces of Cameroon called "Nah po," consumed along with taro. The extract is sourced from Dichrostachys glomerata (sickle bush), commonly used as a spice in the traditional Cameroonian Achu soup — a combination of ground spices, crude palm oil, and aqueous ash extract. This dual role as food spice and medicinal plant is characteristic of its use in the region.

2.2 Traditional Medicinal Use

Dichrostachys glomerata is used in traditional Cameroonian medicine as a natural remedy for many illnesses. Dichrostachys cinerea's bark, roots, and fruit pods are used in traditional medicine as remedies against common health problems such as fever, pain, and diarrhea, and it also has laxative properties.

The plant is largely used ethnomedically across Africa, and mainly employed for the treatment of asthma in Ivory Coast and Gabon. Dichrostachys glomerata, an aromatic plant from the family Fabaceae, is used worldwide as a spice and medicinal drug to cure infertility in men. D. glomerata is used as a traditional herbal medicine from Africa to Sudan, as well as Asia and Australia.

In Nigeria, the pods are known by distinct local names in multiple ethnic traditions (Hausa, Fulani, Yoruba, and Igbo), indicating broad geographic spread of traditional familiarity with the plant across West Africa. Traditional preparations have included decoctions of bark and roots for fever and pain, pod-based preparations for gastrointestinal complaints, and the dried spice in soups as a dietary staple.

3. Key Constituents and Active Compounds

3.1 Polyphenols and Phenolic Acids

The antioxidant activity of aqueous, ethanol, and hydroethanolic pod extracts of Dichrostachys glomerata was investigated; the ethanol extract exhibited the highest phenolic content, AEABTS, and AEDPPH values. The content of phenolic compounds in D. glomerata extracts varied between 307.25 and 493.48 mg catechin equivalent per gram of extract. DPPH radical and ABTS cation radical scavenging activities were demonstrated and correlated with the reductive potential and phenolic content of the extracts; all extracts showed superoxide anion radical, hydroxyl radical, and nitric oxide scavenging activity in a concentration-dependent manner.

Both water and ethanol extracts of the fruit were rich in polyphenolic compounds, mainly flavan-3-ols, proanthocyanidins, and flavone glycosides, which demonstrated important in vitro antioxidant capacity.

3.2 Full Phytochemical Profile

Chemical screening of D. glomerata ethanolic extract revealed the presence of phenols, tannins, triterpenes, saponins, alkaloids, and flavonoids. Phytochemical screening of D. glomerata has been reported to contain bioactive compounds such as flavonoids, anthocyanines, anthraquinones, phenols, and triterpenoids, which are known for their taste-enhancing and anti-inflammatory effects. D. glomerata contains various phytochemical components such as sterols, alkaloids, terpenoids, polyphenols, and glycosides.

The study on the chemical components of D. glomerata fruit showed that it is rich in flavonoids, phenolic compounds, alkaloids, tannins, saponins, and terpenoids. These molecules possess numerous pharmacological activities, including cardioprotective, anti-inflammatory, antimicrobial, antioxidant, and hepatoprotective properties.

3.3 Extraction and Standardization

Phytochemical analysis shows that the extraction solvent influences the compound's concentration and composition; the ethanolic extract had approximately 1.4 times higher values of total phenolic content compared to the water extract. This difference in potency across extraction solvents is relevant to how commercially standardized extracts are produced and labeled.

4. Proposed Mechanisms of Action

4.1 AMPK Signaling Pathway

Research revealed that Dyglomera® inhibited adipogenesis and lipogenesis by regulating AMPK phosphorylation in white adipose tissues (WATs) and 3T3-L1 adipocytes, and promoted lipolysis by increasing the expression of lipolysis-related proteins. Dyglomera® is an aqueous ethanol extract of the fruit pods of Dichrostachys glomerata. Several studies have shown its anti-diabetic and anti-obesity effects, though the underlying mechanisms remain under investigation. This objective was studied in mice with high-fat diet-induced obesity and 3T3-L1 adipocytes. It must be noted that this mechanistic evidence is preclinical (in vitro and mouse model) and has not been directly confirmed in humans.

4.2 GLP-1 and DPP-4 Modulation

Dichrostachys glomerata and Cissus quadrangularis are two species traditionally used in Cameroon, recognized for their weight-reducing potential. A study examined the effects of standardized extracts of these botanicals on glucagon-like peptide-1 (GLP-1), dipeptidyl peptidase-4 (DPP-4), and key metabolic outcomes in individuals with excess body weight. Benefits observed in clinical settings are attributed to the extract's ability to modulate hormones such as glucagon-like peptide-1 (GLP-1), insulin, leptin, and adiponectin, while also reducing oxidative stress. These proposed hormonal mechanisms remain an active area of clinical investigation.

4.3 Antioxidant Activity

Clinical and preclinical research demonstrates that Dichrostachys glomerata, a plant rich in flavonoids, phenolic compounds, alkaloids, tannins, saponins, and terpenoids, is an effective antioxidant that reduces oxidative stress. Reduction in oxidative stress may underlie several of the metabolic and potentially sleep-related effects observed in clinical trials.

4.4 Bronchodilatory Effects (Preclinical)

The plant is largely used ethnomedically across Africa for the treatment of asthma in Ivory Coast and Gabon. A study analyzed the relaxation induced by the methanolic extract of D. cinerea in guinea-pig trachea preparations (GPTPs). These observations suggest the extract could act through two mechanisms: activation of β-adrenergic or histaminergic receptors, with muscarinic receptors apparently not being greatly involved — findings that partially justify the use of the extract in traditional medicine in Africa. This research is preclinical only.

4.5 Antibacterial Activity (Preclinical)

Results of antibacterial assays indicated that extracts from a panel of Cameroonian spices exert antibacterial activities, with minimum inhibitory concentration (MIC) values varying from 32 to 1024 μg/ml. Extracts from Dichrostachys glomerata were among the most active. In the presence of the efflux pump inhibitor PAβN, the activity of the extract from D. glomerata significantly increased on 69.2% of tested multi-drug-resistant (MDR) bacteria, and synergistic effects with chloramphenicol and tetracycline were noted on 75% of tested bacteria at MIC/5. These findings are in vitro only.

5. Scientific Evidence by Health Area

5.1 Body Weight and Obesity

5.1.1 Early Clinical Research (2011)

A study by Kuate et al. (2011) examined the effects of Dichrostachys glomerata spice on cardiovascular disease risk factors in normoglycemic and type 2 diabetic obese volunteers, published in Food Research International, Vol. 44, pp. 1197–1202. This early human study established an initial evidence basis for subsequent controlled trials.

5.1.2 Body Fat Percentage Trial (12-Week RCT)

A 12-week randomized, double-blind, placebo-controlled trial had percentage body fat measured by dual-energy X-ray absorptiometry (DEXA), body weight, and body mass index set as efficacy endpoints, with key biochemical parameters as secondary endpoints. Subjects treated with Dyglomera® for 12 weeks showed significant differences, with a 6.73 kg (p<0.05) decrease in body weight and a 22.85% (p<0.05) reduction in percentage body fat. In addition, markers of lipid profile, adipocytokines, glycemia, and transaminase plasma activities were also improved by Dyglomera® intake.

5.1.3 Metabolic Syndrome RCT (8-Week)

A study evaluated the effects of Dyglomera®, an aqueous extract of DG standardized to NLT 10% polyphenols, on anthropometric, biochemical (including pro-inflammatory and pro-thrombotic states), and hemodynamic parameters in obese patients with metabolic syndrome, using an 8-week randomized, double-blind, placebo-controlled design involving 116 males and 202 females aged between 24 and 58 years. At the end of the study, the Dyglomera® group showed statistically significant differences in all 16 parameters compared to baseline values. Changes in BMI and waist circumference were accompanied by changes in biochemical parameters, with the exception of adiponectin levels which were not correlated to waist circumference and PAI-1 values. The results confirmed that Dyglomera® has anti-inflammatory properties and is effective in reducing cardiovascular disease risk factors associated with metabolic syndrome in obese human subjects.

5.1.4 Oxidative Stress in Obesity and Type 2 Diabetes (8-Week RCT)

A separate work evaluated the effect of Dichrostachys glomerata on the improvement of antioxidant biomarkers in obesity and type 2 diabetes participants, in an 8-week randomized, double-blind, placebo-controlled design study. The active (400 mg) or placebo formulation was administered twice daily throughout the study period to two normoglycemic and two diabetic obese random groups.

5.1.5 Combined Weight and Mood RCT (60-Day)

A study aimed to examine the effect of a standardized powder of D. glomerata fruit pods (DYG-400®) on weight, food cravings, mood, and health-related quality of life of overweight and mildly obese adults. In this CONSORT-compliant double-blind placebo-controlled trial, 56 adults (mean age 44.50, mean BMI 31.66) were randomized to either the D. glomerata Group (300 mg/d) or Placebo Group (rice protein, 300 mg/d) for 60 days. Over 60 days of treatment, the D. glomerata group lost an average of 4.11 pounds compared to 2.19 pounds in the placebo group. There were also significantly greater reductions in self-reported food cravings compared to both baseline and the placebo group, as measured via the Food Cravings Questionnaire.

5.1.6 Combined with Irvingia gabonensis

Weight and blood lipid parameters were measured at baseline and at the 4 and 8-week interval in a study examining Dyglomera® in combination with Irvingia gabonensis extract; compared to the placebo group, there were significant (p<0.05) reductions in weight of participants in both test groups over the 8-week period.

Limitations of the weight-management evidence base: The majority of the human clinical trials examining weight and metabolic outcomes have been funded or supported by Gateway Health Alliances, the commercial developer of the proprietary extracts (Dyglomera®, DygloFit®, DYG-400®, Somnoril™). Researchers themselves called for future research to investigate mechanisms of action, longer-term effects, and generalizability of results to other populations. Independent replication by groups without financial ties to the ingredient is limited at the time of this writing.

5.2 GLP-1 and DPP-4 Modulation (2025–2026 RCT)

In a 16-week, randomized, double-blind, placebo-controlled trial, 248 adults (126 women and 122 men; mean age 41.3 ± 0.3 years; BMI 25–34.9 kg/m²) were assigned to receive 400 mg D. glomerata extract (DGE), 300 mg Cissus quadrangularis extract (CQE), semaglutide (dose-escalated from 3 mg to 14 mg), or placebo, administered once daily. Primary assessments included changes in GLP-1 levels and DPP-4 activity. This trial, published in the journal Medicina (MDPI) and indexed on PubMed (PMID: 41597327), represents one of the most methodologically sophisticated studies to date, directly comparing the extract against semaglutide and placebo in a four-arm design. Full outcome data from this trial should be consulted directly via the primary publication.

5.3 Cardiovascular Risk Factors and Lipid Profile

In previous studies, D. glomerata has demonstrated antioxidant and anti-inflammatory properties, the capacity to regulate fat metabolism, and the ability to lower fasting serum glucose levels and glycated hemoglobin. The 8-week metabolic syndrome RCT detailed in Section 5.1.3 included hemodynamic parameters (blood pressure) and pro-thrombotic markers alongside lipid variables, and reported significant improvements across all 16 measured parameters in the active treatment group versus baseline. These results were published in the peer-reviewed journal Functional Foods in Health and Disease (2013) and have been cross-referenced in subsequent human research.

5.4 Sleep Quality

A double-blind, placebo-controlled pilot trial assessed the effectiveness of Dichrostachys glomerata (Dyglomera®) supplementation on adults' sleep quality and daytime activity. Using 56 adults with non-clinical poor sleep (mean age 44.50), participants were randomized to either the Dichrostachys glomerata Group (300 mg/d) or Placebo Group for 60 days. Outcomes were the self-reported Insomnia Severity Index and objective sleep and daytime activity via the Oura Ring. The Dichrostachys glomerata Group had improved Insomnia Severity Index symptoms, with significant improvements from Day 0 to Day 60. Objective sleep measures indicated that the Dichrostachys glomerata Group had significantly improved sleep score and deep sleep duration, while the Placebo Group declined in these parameters. This trial was published in Medical Research Archives (2024). The small sample size (56 participants) and self-reported nature of the primary endpoint are acknowledged limitations; the authors designated it a pilot trial.

5.5 Anti-inflammatory and Analgesic Effects (Preclinical)

Polyphenol-rich extracts administered in three different concentrations for 30 days in a Freund's adjuvant-induced arthritic rat model were evaluated for pain threshold, thermal hyperalgesia, edema, and serum biomarkers specific to inflammatory processes or oxidative stress. Both fruit extracts showed the maximum antinociceptive capacity in this preclinical model. This research is animal-only and does not constitute clinical evidence of analgesic efficacy in humans.

5.6 Respiratory (Preclinical / Traditional Only)

As detailed in Section 4.4 above, the bronchodilatory properties observed in isolated guinea-pig trachea preparations provide a partial mechanistic explanation for the traditional use of the plant for asthma in Ivory Coast and Gabon. No human trials on respiratory endpoints have been identified in the literature.

5.7 Male Reproductive Health (Preclinical Only)

Dichrostachys glomerata is used in Cameroonian traditional medicine to treat infertility in men. One preclinical study was designed to highlight the effects of the ethanolic extract of D. glomerata on oxidative status, serum metabolites, and reproductive characteristics in female guinea pigs. No human clinical trials specifically addressing male or female fertility endpoints in humans have been identified in the peer-reviewed literature.

6. Body Systems and Health Areas of Association

Metabolic system: Weight management, body fat percentage, BMI, waist circumference, blood glucose, glycated hemoglobin (HbA1c), insulin sensitivity, GLP-1 and DPP-4 modulation. Evidence from multiple human RCTs, ranging from moderate to early-stage.
Cardiovascular system: Lipid profile (total cholesterol, LDL, HDL, triglycerides), blood pressure, pro-inflammatory markers (C-reactive protein), pro-thrombotic markers (PAI-1). Evidence from human RCTs.
Adipose tissue biology: Adipocytokines (adiponectin, leptin), adipogenesis and lipogenesis inhibition via AMPK. Evidence predominantly preclinical (mouse and cell models).
Antioxidant / oxidative stress: DPPH, ABTS, hydroxyl radical, superoxide anion scavenging demonstrated in vitro; antioxidant biomarker improvements shown in human RCTs in obese/diabetic participants.
Sleep and circadian health: Insomnia Severity Index scores, objective sleep duration and deep sleep, daytime activity. Evidence from one small pilot RCT.
Mood and quality of life: Food cravings, psychological quality-of-life measures. Evidence from clinical studies in overweight/obese adults.
Immune / antimicrobial: Antibacterial activity against Gram-negative MDR bacteria demonstrated in vitro only.
Respiratory: Bronchodilatory effects shown in isolated tissue preparations only; traditional use for asthma documented ethnobotanically.
Gastrointestinal: Traditional use for diarrhea, abdominal pain, and digestive complaints documented; no controlled clinical trials identified on GI endpoints.

7. Dosage Forms and Dosages Reported in Studies

The following dosages reflect those reported in the primary published literature and should not be interpreted as prescriptive recommendations:

Dyglomera® (aqueous extract, standardized to NLT 10% polyphenols): used in an 8-week RCT involving 318 participants aged 24–58 years with metabolic syndrome.
400 mg active formulation (or matched placebo) administered twice daily in an 8-week randomized, double-blind, placebo-controlled design in normoglycemic and diabetic obese groups.
12-week randomized, double-blind, placebo-controlled trial using Dyglomera®, with percentage body fat by DEXA as the primary endpoint.
DYG-400® standardized fruit pod powder at 300 mg/day for 60 days in a trial measuring weight, food cravings, mood, and quality of life in 56 overweight/mildly obese adults.
300 mg/day of Dichrostachys glomerata extract for 60 days in the pilot sleep quality trial (n=56).
400 mg D. glomerata extract (DGE) once daily for 16 weeks in the GLP-1/DPP-4 randomized controlled trial (n=248).
400 mg is listed as the recommended adult daily serving for the Dyglomera®/DygloFit® ingredient as stated by the manufacturer Gateway Health Alliances.

In the preclinical toxicology studies, Sprague Dawley rats were gavaged with D. glomerata extract at dose levels of 0, 100, 1000, and 2500 mg/kg body weight/day for 90 days.

8. Safety Considerations

8.1 Subchronic Toxicity (90-Day Rat Study)

Given the potential uses of D. glomerata fruit pod extract as a dietary supplement and the lack of safety-related information, adverse effects of Dyglomera™ were investigated in a long-term repeat-dose toxicity study and in genotoxicity studies. In the repeat-dose subchronic toxicity study, a detailed assessment of the toxic potentials of a standardized ethanolic extract of D. glomerata extract (Dyglomera™) prepared from dried fruits was undertaken when administered daily for 90 days via oral gavage to Sprague Dawley rats.

Dyglomera™ administration did not result in mortality or show treatment-related changes in clinical signs of toxicity, body weights, body weight gain, or feed consumption. No toxicologically significant treatment-related changes in hematological, clinical chemistry, urinalysis parameters, and organ weights were noted. Macroscopic and microscopic examinations did not reveal treatment-related abnormalities.

Mutagenic and clastogenic potentials as evaluated by the Ames assay, in vitro and in vivo chromosomal aberration test, and in vivo micronucleus test did not reveal any genotoxicity of the extract. The results of the subchronic toxicity study support a no-observed-adverse-effect level (NOAEL) for D. glomerata extract of 2500 mg/kg bw/day, the highest dose tested.

This study (published in Food and Chemical Toxicology, 2014, PMID: 24713264) was conducted partly by Gateway Health Alliances — the commercial developer of the ingredient — which is a relevant conflict-of-interest consideration when interpreting the findings. No independent replication of this NOAEL in another laboratory has been identified.

8.2 Genotoxicity Panel

The potential genotoxic effects of D. glomerata fruit extract were investigated in a bacterial reverse mutation assay (Ames test) using Salmonella typhimurium strains, an in vitro mammalian chromosomal aberration assay in CHO-K1 cell line, an in vivo chromosomal aberration study in rats, and an in vivo mammalian erythrocyte micronucleus test in rats. All four assays were negative for genotoxic activity at the concentrations tested, as reported in the same publication.

8.3 Human Tolerability

Kuate et al. (Food Research International, Vol. 44, Issue 4, pp. 1197–1202, 2011) reported the potential antioxidant and hypoglycemic properties of the spice and that it is well tolerated in humans. The clinical trials conducted to date have not reported serious adverse events attributable to D. glomerata extract, though formal adverse-event reporting across the available trials has been variable and the studies are of relatively short duration (8–16 weeks).

8.4 Preclinical Signals Warranting Attention

In guinea pigs treated with ethanolic extract of D. glomerata, the serum content of total proteins, albumin, globulins, ALT, and creatinine concentrations were not significantly affected compared to control; however, serum total cholesterol and AST significantly increased with increasing doses of extract (p<0.05). This dose-dependent elevation in AST in guinea pigs warrants attention as a potential hepatic signal, though it was not replicated as a pathological finding in the 90-day rat study. These are animal data only and their relevance to humans at supplemental doses is unclear.

8.5 Populations and Interactions: Known Data Gaps

No controlled clinical data have been identified in the peer-reviewed literature specifically evaluating D. glomerata supplementation in pregnant or breastfeeding women, children, or adolescents. Given its reported capacity to modulate GLP-1, insulin, and other glucoregulatory hormones, a pharmacodynamic interaction with insulin secretagogues, DPP-4 inhibitors, or GLP-1 receptor agonists (e.g., semaglutide) is biologically plausible and clinically relevant. The GLP-1/DPP-4 clinical trial (2025) directly compared DGE to semaglutide in separate arms but did not study combined administration. No herb-drug interaction studies have been identified in the peer-reviewed literature.

9. Overall Assessment of the Evidence Base

The body of human clinical evidence for Dichrostachys glomerata is relatively small but expanding. Four randomized clinical trials involving approximately 550 subjects have been reported to demonstrate significant weight loss and improvements in metabolic balance and wellness. The most rigorous of these are randomized, double-blind, and placebo-controlled, which represents a meaningful level of clinical evidence for a botanical ingredient. However, several important caveats apply:

The clinical research has been predominantly conducted or sponsored by the same commercial entity (Gateway Health Alliances) that produces the proprietary extracts. Independent replication is limited.
Trial durations have generally been short (8–16 weeks), and long-term effects beyond this window have not been studied in controlled conditions.
Sample sizes in the available RCTs range from 56 to 318 participants, providing moderate statistical power but limited generalizability.
Researchers have called for future research to investigate mechanisms of action, longer-term effects, and generalizability of results to other populations.
Mechanistic studies at the cellular and animal levels (AMPK activation, GLP-1 modulation) offer a biologically plausible framework for the observed clinical outcomes, but direct mechanistic confirmation in humans is still needed.

In summary, Dichrostachys glomerata has a genuine and well-documented traditional use in West and Central African food and medicine cultures. Its phytochemistry is well-characterized and includes established bioactive classes. The clinical evidence for weight management, metabolic syndrome parameters, and antioxidant effects in obese adults is preliminary but encouraging, with several randomized controlled trials showing significant effects. Sleep-related and mood-related evidence is at a very early, pilot stage. The safety profile from preclinical testing is favorable at the doses tested, and short-term human trials have not documented serious adverse events. The ingredient does not currently hold an approved health claim from major regulatory bodies such as the European Food Safety Authority (EFSA) or the U.S. Food and Drug Administration (FDA), and it has not been the subject of a WHO monograph or a Commission E monograph.

References

Health Conditions

Health conditions that Dichrostachys glomerata may help support.

No conditions available.

Body Systems

Body systems that Dichrostachys glomerata may help support.

No body systems available.